Secukinumab, a fully human anti‐interleukin‐17A monoclonal...

  • Main
  • 2019 / 04
  • Secukinumab, a fully human anti‐interleukin‐17A monoclonal...

Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years

Reich, K., Blauvelt, A., Armstrong, A., Langley, R G., de Vera, A., Kolbinger, F., Spindeldreher, S., Ren, M., Bruin, G.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Journal of the European Academy of Dermatology and Venereology
DOI:
10.1111/jdv.15637
Date:
April, 2019
File:
PDF, 930 KB
english, 2019
Conversion to is in progress
Conversion to is failed